Abstract
Histone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of various human diseases including cancer, neurodegenerative disease and immunology due to its unique structure, substrate and biological functions. HDAC6 is involved in cell motility, cell survival, cell cycle progression, developmental events, prognosis as well as protein degradation and the involvement of HDAC6 in multiple biological processes has gained lots of attention. There is increasing interest in HDAC6 and its selective inhibitors. More than twenty years of synthetic efforts have developed various HDAC6 selective inhibitors with different Cap, linker and ZBG. This review will summarize recent research data regarding HDAC6 and various HDAC6 selective inhibitors.
Keywords: Epigenetics, HDAC6, Protein degradation, Neurodegenerative disease, Cancer, HDAC6 selective inhibitors.
Current Topics in Medicinal Chemistry
Title:Structure, Functions and Selective Inhibitors of HDAC6
Volume: 18 Issue: 28
Author(s): Tao Liang and Hao Fang*
Affiliation:
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China
Keywords: Epigenetics, HDAC6, Protein degradation, Neurodegenerative disease, Cancer, HDAC6 selective inhibitors.
Abstract: Histone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of various human diseases including cancer, neurodegenerative disease and immunology due to its unique structure, substrate and biological functions. HDAC6 is involved in cell motility, cell survival, cell cycle progression, developmental events, prognosis as well as protein degradation and the involvement of HDAC6 in multiple biological processes has gained lots of attention. There is increasing interest in HDAC6 and its selective inhibitors. More than twenty years of synthetic efforts have developed various HDAC6 selective inhibitors with different Cap, linker and ZBG. This review will summarize recent research data regarding HDAC6 and various HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Liang Tao and Fang Hao *, Structure, Functions and Selective Inhibitors of HDAC6, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026619666181129141822
DOI https://dx.doi.org/10.2174/1568026619666181129141822 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Subject Index To Volune 2
Current Cancer Therapy Reviews Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery Editorial: [Hot Topic: New Approaches in the Treatment of Multiple Myeloma: From Target-based Agents to the New Era of microRNAs (Dedicated to the Memory of Prof. Salvatore Venuta)]
Current Cancer Drug Targets Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Application of Chiral α-Monofluorocarbonyl Compounds to Analytical and Medicinal Chemistry
Current Organic Chemistry Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets Dendritic Cell-Based Immunotherapy in Thyroid Malignancies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Topoisomerase I and II Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Current Vascular Pharmacology Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets